Skip to content

Thoracic Mobilization Versus Counterforce Forearm Brace in Treatment of Lateral Elbow Tendinopathy

Thoracic Mobilization Versus Counterforce Forearm Brace in Treatment of Lateral Elbow Tendinopathy (Randomized Control Trail)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07113912
Enrollment
40
Registered
2025-08-11
Start date
2025-03-25
Completion date
2025-08-20
Last updated
2025-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lateral Elbow Tendinopathy

Brief summary

The study aim to compare the effect of thoracic mobilization versus counterforce forearm brace in treatment of LET. Detailed Description: Conditions: Lateral elbow tendinopathy Keywords: LET, Tennis elbow, Thoracic mobilization & counterforce forearm brace.

Interventions

DEVICEcounterforce forearm brace

a flexible band that fits around the proximal forearm, applying pressure to underlying tissues during activity to potentially reduce acceleration forces and alleviate pain associated with conditions like lateral epicondylitis.

PROCEDUREthoracic immobilization

the methods and devices used to restrict movement of the thoracic spine, which is the upper and middle part of the back.

Sponsors

Deraya University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients clinically diagnosed as lateral elbow tendinopathy. * Positive clinical sign on the following: Cozen's test Mill's test and Maudsley's test * Pain involving in age group of 18-55 years * Patients complaining from unilateral elbow pain, more than 3 months

Exclusion criteria

* Previous Surgery or Intervention (e.g., tendon release, debridement, or joint replacement) in the affected shoulder/elbow are excluded * Presence of systemic conditions affecting tendon healing like rheumatoid arthritis, diabetes, or other systemic diseases that impair tendon healing or exacerbate pain can confound results * Severe Comorbidities Such as Severe cardiovascular, neurological, or musculoskeletal disorders

Design outcomes

Primary

MeasureTime frameDescription
Visual Analog Scale (VAS)4 weeksconsists of a 10 cm (or 100 mm) horizontal or vertical line, where 0 indicates no pain, and 10 (or 100 mm) represent the worst imaginable pain

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026